Provectus gains patent allowance for PH-10 in the EU

Knoxville, Tenn.

- Provectus Pharmceuticals has received allowance of its patent application in the European Union for PH-10, as well as other related agents and their use, according to Businesswire.

The pending patents cover topical applications for treatment of psoriasis and eczema. Currently, PH-10 is undergoing a phase 2 clinical trial in New York City for the treatment of moderate to severe psoriasis, Businesswire reports.